Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
Omics International publishes 304 Open Access Articles in 13 International Journals it has 32 Upcoming Conferences and 15 Previous Conferences with 581 Conference Proceedings and 92 National symposiums.
The data on side effects were tabulated for patients taking at least one of the following atypical antipsychotic medications: paliperidone,olanzapine, quetiapine, risperidone, aripiprazole, or ziprasidone. As a result of taking an atypical antipsychotic medication approximately there is 54% of the 353 respondents have experienced a side effect. Most common side effects includes: weight tiredness/lethargy, gain/hunger, and lack of coordination/muscle problems, such as twitches, tenderness, and tremors.The atypical antipsychotics (AAP) (otherwise called Second Generation Antipsychotic Medications (SGAs) are a group of medications used for treating some psychiatric conditions. Some SGAs are FDA-approved for use in the treatment of acute mania, bipolar disorder, schizophrenia, and bipolar mania and other mental illness conditions.
OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that OMICS Group hosts over 700 edge peer reviewed Open Access Journals and organizes over more than 1000 Global Events annually. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 75000+ eminent personalities that ensure a quality and quick review process checker.
Second Generation Antipsychotic Medications (SGAs) are also referred to as atypical antipsychotics. The term "atypical" refers fact that they generally do not cause the same degree of movement side effects that are common to the first generation, or so-called “typical" antipsychotics. The major players in the antipsychotics market include AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, Pfizer, and GlaxoSmithKline. Eli Lilly's Zyprexa has the largest market share of the market, at 27% ($4.72 billion), while AstraZeneca's Seroquel, at 2nd place ($4.45 billion) remains the most widely prescribed antipsychotic. Bristol-Myers Squibb's Abilify, which was approved for market release in 2007, saw a 31% growth in sales from 2007 to 2008 to $2.15 billion, making it the fastest growing therapeutic in the antipsychotics market.
Antipsychotic medications are now the largest-selling class of drugs in the U.S. They have grown from a niche product to the king of blockbusters, accounting for more than $14.6 billion in annual sales.
List of Best International Conferences
Related Associations and Societies
The Society for Neuroscience
Society for Neuro-Oncology
American Physiological Society (APS)
American Medical Associations
American Autonomic society
America cancer society
Euro CNS
Canadian nuclear society
American Clinical Neurophysiology Society
American Academy of Neurology
European Neurological Societies
World Federation of Neurology
Spanish Society of Neurology
Hilarescere Foundation in Italy
Italian MS society in Italy
Southern Clinical Neurological Society
ESNR European Society of Neuroradiology
Vision sciences society
American Association of Neurological Surgeons
Saudi Association of Neurosurgery
Emirates Medical Association
Top Market key players:
AstraZeneca plc
Eli Lilly & Co.
Johnson & Johnson
Pfizer
GlaxoSmithKline,
Novartis AG,
Sanofi,
Merck & Co.,
Abbott Laboratories,
UCB,
Bristol-Meyers Squibb Co.
Astellas Pharma
Cordis Corporation
Boston Scientific Corporation
Siemens AG
Genentech, Inc.
Koninklijke Philips N.V.
Medtronic plc
GE Healthcare
Stryker Corporation
Abbvie
Impax labs
Hospira
Genzyme
Forest Laboratories
Chelsea therapeutics
Upshers-smith laboratories
The World Health Organization (WHO) shows that 6.8 million people die every year as a result of neurological disorders, in Europe the economic cost of neurological diseases was estimated at about 139 billion euros in 2004. Total European 2010 cost of brain disorders was €798 billion and will grow to $480 billion by 2030
This page will be updated regularly.
This page was last updated on December 23, 2024
